Introduction {#Sec1}
============

Primary total hip replacement (THR) is actually one of the most common procedures in orthopaedic elective surgery, but still involves considerable bleeding and a high transfusion rate \[[@CR1]\]. Several methods have been used to manage blood loss including intravenous medication, topical application, bipolar sealer or electrocautery.

This investigation compares the use of fibrin spray with bipolar sealer as blood conservation methods in primary cementless THR. Their ability to save blood has been described separately, but no reports have compared them in the THR procedure.

The fibrin spray used (Quixil, Omrix Biopharmaceuticals, Belgium, distributed by Johnson&Johnson Medical) consists of two separate solutions (Active Biological Component and Thrombin) mixed and nebulised at the surgical site; it acts independently of the recipient's coagulation system, unlike tranexamic acid. The bipolar sealer used (Aquamantys Tissue Link Medical, Inc, Dover) is a bipolar, radiofrequency coagulation system delivering a saline solution that produces localised cooling (reducing echar formation).

Estimated blood loss and effecacy of the two methods to reduce peri- and post-operative bleeding compared to standard electrocautery were the endpoints of this investigation.

Patients and methods {#Sec2}
====================

We designed a prospective randomised controlled trial, recruiting our cases from December 2009 through March 2011. It was a single-centre, single-surgeon, single-blind trial, conducted with the approval of the Hospital Ethical Committee.

Each eligible patient (see inclusion and exclusion criteria) was informed about the trial purpose and methods and a specific consent for the use of blood and plasma derived products were collected before definitive recruitment. The study groups (see Table [1](#Tab1){ref-type="table"}) were set up from patients scheduled to undergo elective primary cementless total hip replacement (unilateral).Table 1Study groupsStudy groupPatientsControl38Fibrin spray31Bipolar sealer26

To determine sample size we considered, in analogy to other studies available in literature \[[@CR2], [@CR3]\], a difference of at least 30 % in peri-operative blood loss as clinically significant. Considering a mean blood loss post-operatively detected close to 1000 ml in most articles, a blood volume saved between 250 and 300 ml could be considered clinically relevant \[[@CR4]\]. Assuming an average blood loss of 1066 ml ± 441 (standard deviation) as in other papers \[[@CR5]\], to detect this difference at a 5 % significance level and at 80 % of power, a sample size of 26 patients or more per group was needed. To eliminate possible bias related to the procedure, operations were conducted by the same surgeon, through the same surgical approach (direct lateral in lateral position) and under the same anaesthesia (spinal).

Inclusion criteria were: age between 45 and 75 years; pre-operative haemoglobin levels equal or greater than 11 g/dL; PT, PTT, INR and fibrinogen values within the normal range. The age distribution between groups was similar (see Table [2](#Tab2){ref-type="table"}) to reduce a possible bias related to the age of the patients.Table 2Age distribution between groupsStudy groupAge (years)45--5556--6566--75TotalControl6161638Fibrin spray5141231Bipolar sealer491326Overall total15394195

Exclusion criteria were: use of anti-platelet aggregating drugs or anticoagulant medications; a known coagulopathy or haemolytic disease; previous thrombo-embolism; previous reaction to blood products; and liver failure. In case of protocol violation, the subject involved was excluded and replaced with a newly-recruited one. The recruitment was stopped when each group had at least 26 patients. Data collection was performed by the attending physician, while statistical analysis was undertaken by an independent statistician.

At admission (usually 24 hours before surgery), patient weight and morphotype (obese, normal, thin, muscular) were recorded to calculate extimated blood volume (EBV) (see Table [3](#Tab3){ref-type="table"}); blood tests for full blood count, electrolytes, liver function, urea and renal function, clotting and cross-match were obtained.Table 3Estimated blood volume (ml per kg) as a function of body habitus, gender and body weightBody HabitusMaleFemaleObese6055Thin6560Normal7065Muscular7570

Each subject received a standard DVT prophylaxis with Enoxaparin 4000 units 12 hours after surgery, paired with elastic stockings and foot-calf pumps immediately after surgery.

Single-blinding of the study was an implicit limit of this investigation, because it is not possible to blind the surgeon to the use of a bipolar sealer or fibrin spray instead of a standard electrocautery. On the other hand, patients and staff members (attending physician, nurses, laboratory technicians) remained blinded.

Patients randomised to the fibrin spray group received topical applications of a combination of two components (supplied in separate vials): (1) a biological active component (BAC)---a concentrated solution of human clottable proteins (fibrinogen and fibronectin) and an antifibrinolytic agent (tranexamic acid); (2) human thrombin---a high potency solution of purified human thrombin and calcium chloride for activation of clotting of the final combined product.

We prefer application of the fibrin spray at the end of the procedure, before closure; during surgery, largest vessels need, on our advice, standard electrocautery or ligature. Moreover, the thin layer derived from application may be altered from lavages and swabs before the procedure was accomplished.

Patients randomised to the bipolar sealer group received a continuous haemostatic action, using the device in a painting motion or as spot treatment for bleeding vessels.

The bipolar sealer provides haemostasis at 100 °C or less because it delivers radiofrequency to saline; this temperature is lower than those of conventional electrocautery and does not char or burn tissue during haemostatic sealing and coagulation of soft tissue.

An articular drainage activated by means of low pressure and three non-return valves (Bellovac™ Astra Tech) was used at the end of each procedure; re-infusion was planned six hours after completion of surgery (recording blood volume collected), and each patient underwent full blood count prior to re-infusion.

Full blood count was repeated at given intervals (24, 48 and 72 hours) and eventual further blood transfusion was recorded.

To obtain the peri-operative blood loss we applied a formula described by Jeffrey B. Gross (corrected for dilution in its logarithmic version) \[[@CR6]\] considering the blood volume eventually re-infused: $\documentclass[12pt]{minimal}
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Data for the three treatments (fibrin spray, bipolar sealer, standard electrocautery) were analysed performing a pair-wise comparison between the sample means of each active treatment and control, using the Student\'s t-test. Data collection and analysis was performed with the Microsoft Excel tool (Microsoft Corporation, Redmond, Washington) and software R2.13.1.

Results {#Sec3}
=======

No adverse effects were detected during the trial, enabling us to complete patient recruiting and data collection. Patients excluded from the study because of protocol violation (one received Dabigatran as oral prophylaxis against DVT, three missed one or more total blood count, two received a non-recorded volume of re-infused blood from drainage) were replaced by newly recruited subjects. When at least 26 cases had been collected in all groups, the recruitment was stopped and data analysis was performed. A total of 95 patients were available for data analysis. Calculated blood loss at the given intervals is summarised in Table [4](#Tab4){ref-type="table"} (mean values).Table 4Calculated blood loss for each group at given intervalsStudy groupBlood Loss (ml) at given intervals6 h24 h48 h72 hControl (38 cases)960157320161862Fibrin spray (31 cases)72512051373Bipolar sealer (26 cases)864144417191741Mean85714171694

Control group (standard electrocautery) showed a mean post-operative blood loss of 960 ml at 6 hours, 1573 ml at 24 hours, 2016 ml at 48 hours and 1862 ml at 72 hours. Comparing the fibrin spray group with the control group, we detected a blood savings at 6, 24, 48 and 72 hours of 235, 368, 642 and 490 ml, respectively. Comparing the bipolar sealer group with the control group, we detected a blood savings at 6, 24, 48 and 72 hours, of 96, 129, 296 and 121 ml, respectively.

Considering each given interval from surgery, we calculated the statistical significance (Student\'s t-test, interval of confidence 95 %). These differences were statistically significant (Student\'s t-test,*p* = 0.05) in all intervals considered between the fibrin spray group and control, while for comparison between the bipolar sealer and control groups a significant difference was observed only at 48 hours (see Table [5](#Tab5){ref-type="table"}).Table 5Output of statistical comparison between results achieved in treatment groups (*FS* fibrin spray, *BS* bipolar sealer) and control group (Student\'s t-test, 95 % confidence interval). The null hypothesis states that the two treatments have the same results as controlGroups comparedTime after surgery6 h24 h48 h72 hFS--Control*t* = 2.1688*t* = 2.906*t* = 4.1706*t* = 3.1242*df* = 58*df* = 67*df* = 58*df* = 61*p*-value \< 0.05 (0.03421)*p*-value \< 0.05 (0.004957)*p*-value \< 0.05 (0.0001028)*p*-value \< 0.05 (0.002663)Null-hypothesis rejectedNull-hypothesis rejectedNull-hypothesis rejectedNull-hypothesis rejectedBS--Control*t* = 0.8406*t* = 1.0762*t* = 2.0899*t* = 0.7725*df* = 56*df* = 62*df* = 53*df* = 61*p*-value \> 0.05 (0.4042)*p*-value \> 0.05 (0,286)*p*-value \< 0.05 (0.04144)*p*-value \> 0.05 (0.4428)Null-hypothesis can't be rejectedNull-hypothesis can't be rejectedNull-hypothesis rejectedNull-hypothesis can't be rejected

Discussion {#Sec4}
==========

As often underlined in clinical practice, blood is a finite resource that needs careful and uninterrupted review of possible areas as to where to improve its use (minimising waste and reducing clinical demand). Total hip replacement, due to its worldwide application (with a progressive increase in number of cases per year) and its peri-operative blood transfusion rate (still considerable, even in the presence of minimally invasive surgery), is probably one of the most remarkable fields of application where blood saving procedures may realise significant results.

We strongly believe that in surgical practice blood loss calculated from suction drains and swabs underestimate the real peri-operative bleeding (not considering hidden losses, i.e. post-operative haematoma); this underestimation extends up to 26 % in total hip replacement, as observed previously \[[@CR7]\]. This is the reason why we use a validated formula to estimate blood loss; that formula, in the natural logarithmic fashion used in our study, is probably not suited for routine use in O.R. to estimate volume to be replaced, but it has been shown to correspond accurately to measured blood losses in humans \[[@CR8], [@CR9]\] and animals.

Most previous studies have detected blood loss in a single post-operative period (often immediately after surgery) and their results reflect this aspect with a limited total volume of blood lost; in our study the total blood loss appears to be higher because its detection has been extended through the first 72 hours after surgery (on the other hand, our mean blood loss values at six hours after surgery are similar to results reported in the literature). Extending our investigation through 72 hours after surgery (in consideration of possible post-operative bleeding), we must consider the possibility of re-infusion from drainage or transfusion during that period (even if there is a potential bias derived from a spontaneous subjective response to anaemia).

Two more considerations should be taken into account resulting from of post-operative re-infusion with autologus blood. Specifically, there may be a deficit in haemoglobin concentration due to haemolysis in the re-infused blood (however, in the presence of low suction pressure devices, appreciable haemolysis has not been detected in a previous study focussed on hidden blood loss in total hip and knee surgery \[[@CR7]\]). A randomised controlled blinded prospective study, analysing the potential benefit using an autologus blood transfusion system, detected no significant advantages (in post-operative haemoglobin levels, number of homologous blood transfusions, clinical outcomes) compared with patients that received no drain \[[@CR10]\].

As reported in our results, the ability of fibrin spray in bleeding control seems to outperform bipolar sealer at every time interval considered. We interpret this behaviour as a limit of the bipolar sealer in reducing local bleeding when blood pressure and body temperature return to normal values in the post-operative period (even in the presence of an extensive use of this device through the different layers of the surgical approach).

Some investigations, to confirm this interpretation, have changed bipolar sealer perspectives detecting no significant differences between the treatment and control groups in terms of the need for blood transfusions or overall blood loss \[[@CR11], [@CR12]\].

On the other hand, the fibrin film sprayed on the surface may act even a few hours after the end of surgery and may prevent bleeding from the bone surface (where the use of the Bipolar sealer is not recommended).

The mean blood savings compared to control treatment was, in the presence of the fibrin spray, between 235 and 642 ml. It is remarkable in terms of clinical significance (a reduction of one red-cell unit for transfusion) and statistical significance (*p* \< 0.05), more than observed with the Bipolar sealer (included between 96 and 296 ml), even if a direct comparison between the two methods was not an objective of the present study.

The potential benefit derived from avoiding one or more transfusion may exceed the biological risk generically ascribed to pathogens. Most previous studies have reported an increased risk of postoperative infections including pneumonia, short-term mortality, length of hospital stay and systemic inflammatory response syndrome in patients treated with one or more blood transfusion \[[@CR13]\]. A cost-effectiveness analysis, finally, should lead surgeons to take into account the impact of additional devices in routine practice, e.g. even in this case, the potential benefit derived from the fibrin spray seems to justify the additional charges.

Previous studies, however, have underlined how cheaper strategies (such as tranexamic acid, TA), may surpass the fibrin spray in term of costs. The therapeutic dose of TA set at 10 mg/kg at induction of anaesthesia will cost in our country about 8€; a Quixil fibrin spray set (two 5 ml vials and nebuliser) costs between 450€ and 675,00€ \[[@CR4]\]; an Aquamantys Bipolar Sealer set costs up to 1440,00€.

But considering tranexamic acid, the manufacturer does not give a recommended dose for surgery and most actual protocols are only based upon clinical observation, giving potential risks of under- or over-dosage. In the literature we can find studies with single doses of 10 mg/kg at the induction of anaesthesia \[[@CR4]\], higher doses \[[@CR14]\] or multiple doses \[[@CR15]\]. Moreover, the same dose can have different effecacy if administrated at the induction or at the end of surgery \[[@CR16]\], and it is difficult to state whether its effect continues even at a period of six or more hours after surgery.

Fibrin spray and of course bipolar sealer, if correctly used, are definitely topical treatments, with minimal or no risks of interference with coagulation away from the surgical site (unlike tranexamic acid, that is based on an intra-venous administration) and both of them act independently from the recipient's coagulation system (while tranexamic acid acts mainly by reducing fibrinolysis, inhibiting plasminogen with a competitive action, depending on the patient's coagulation for clot formation). These mechanisms of action make fibrin spray more selective for the surgical site and potentially expand their application to the patient affected by coagulopathy.

A potential detriment to the use of fibrin spray could be the potential risk of disease transmission; processing and screening are able to eliminate all pathogens, but concern may remain relating to unknown vectors.

A new frontier could be represented by autologous fibrin sealants prepared from blood donated prior to surgery through centrifugation, after a freeze-and-thaw process repeated twice and again centrifuged, and thus obtaining an autologous cryoprecipitate (to be mixed in a double-syringe spray with a second solution composed of thrombin, calcium chloride and aprotinin). This autologous fibrin spray, used in hip surgery, has shown statistically significant results in bleeding control \[[@CR17]\].

Statistical analysis was conducted by Dr. Chiara Pedone (statistician).
